💨 Abstract

The Phase 1 clinical trial of the personalized mRNA vaccine autogene cevumeran for pancreatic cancer, published in Nature, showed promising results. The vaccine activated tumor-specific immune cells that persisted for up to four years in some patients, reducing the risk of cancer recurrence at a three-year follow-up.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖